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Abstract
Dibutyltin (DBT) is used to stabilize polyvinyl chloride (PVC) plastics (including pipes that 
distribute drinking water) and as a de-worming agent in poultry. DBT is found in human blood, 
and DBT exposures alter the secretion of tumor necrosis factor alpha (TNFα) and interferon 
gamma (IFNγ) from lymphocytes. Interleukin 1 beta (IL-1β) is a pro-inflammatory cytokine that 
regulates cellular growth, tissue restoration, and immune response regulation. IL-1β plays a role in 
increasing invasiveness of certain tumors. This study reveals that exposures to DBT (24 h, 48 h, 
and 6 day) modify the secretion of IL-1β from increasingly reconstituted preparations of human 
immune cells (highly enriched human natural killer (NK) cells, monocyte-depleted (MD) 
peripheral blood mononuclear cells (MD-PBMCs), PBMCs, granulocytes, and a preparation 
combining both PBMCs and granulocytes (PBMCs+granulocytes)). DBT altered IL-1β secretion 
from all cell preparations. Higher concentrations of DBT (5 and 2.5 μM) decreased the secretion 
of IL-1β, while lower concentrations of DBT (0.1 and 0.05 μM) increased the secretion of IL-1β. 
Selected signaling pathways were examined in MD-PBMCs to determine if they play a role in 
DBT-induced elevations of IL-1β secretion. Pathways examined were IL-1β converting enzyme 
(Caspase-1), mitogen-activated protein kinases (MAPKs), and nuclear factor kappa B (NFκB). 
Caspase 1 and MAPK pathways appear to be utilized by DBT in increasing IL-1β secretion. These 
results indicate that DBT alters IL-1β secretion from human immune cells in an ex vivo system 
utilizing several IL-1β regulating signaling pathways. Thus, DBT may have the potential to alter 
IL-1β secretion in an in vivo system.
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Introduction
Dibutyltin (DBT) is an organotin compound that is used as a stabilizer in polyvinyl chloride 
(PVC) plastics (Roper, 1992). It is found in drinking water and other beverages due to 
leaching from PVC plastics used in the distribution of drinking water and storage of 
beverages such as fruit juices (Forsyth et al., 1992, 1997; Sadiki et al., 1996). DBT is also 
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found in some plastic food containers (Nakashima et al., 1990; Yamada et al., 1993) and can 
leach into food stored in these containers. Use as a de-worming agent in poultry has also 
lead to its presence in some poultry products (Epstein et al. 1991). Additionally, it is a 
breakdown product of another organotin, tributyltin (TBT), which also heavily contaminates 
the environment (Ohhira et al., 2003; Ueno et al., 2003). DBT has been found in human 
blood samples ranging as high as 0.3 μM (Kannan et al., 1999; Whalen et al., 1999).
Interleukin 1 beta (IL-1β) is a cytokine that stimulates the inflammatory response as well as 
cellular growth and tissue reconstruction (Apte et al., 2006; Arend, 2002; Dinarello, 1996; 
2005; 2009). IL-1β is secreted by a variety of cell types including; monocytes, macrophages, 
T cells, natural killer (NK) cells, keratinocytes, and fibroblasts (Burger and Dayer, 2002; 
Dinarello, 2005; Apte et al., 2006; Voronov et al., 2002). It is initially synthesized as a 31-
kDa protein (termed pro-IL-1β), which is then processed by Capase-1 to its active form (17-
kDa) (Swaan et al., 2001; Dinarello, 1996). Caspase-1 (Kuida et al., 1995; Swaan et al., 
2001), is activated by the caspase activating complex, also known as the inflammasome, 
(Franchi et al., 2009; Lopez-Castejon and Brough, 2011; Martinon et al., 2002). IL-1β can 
also be secreted by neutrophils; however, the processing may be independent of Caspase-1 
(Guma et al., 2009). IL-1β can act as a co-stimulator of the production of interferon gamma 
(IFNγ), another pro-inflammatory cytokine, in natural killer (NK) cells (Cooper et al., 
2001). This multiple-action cytokine contributes to chronic inflammation in diseases such as 
rheumatoid arthritis and multiple sclerosis (Choy and Panayi, 2001; Lucas and Hohlfeld, 
1995). Chronic inflammation also contributes to cancer cell growth. Elevated IL-1β levels 
occur in breast and pancreatic cancers and melanoma (Arlt et al., 2002; Elaraj et al., 2006; 
Jin et al., 1997; Lewis and Varghese, 2006; Muerkoster et al., 2006). It has been shown to be 
required for angiogenesis and invasiveness of both prostate tumors and melanoma in a 
mouse model (Voronov et al., 2002). Elevation of IL-1β boosts the ability of malignant cells 
to become adhesive and invade neighboring tissues at the tumor development site (Vidal-
Vanaclocha et al., 1996). Poor prognoses in patients with breast, colon, and lung cancers as 
well as melanomas have been associated with increased IL-1β production (Lewis and 
Varghese, 2006; Voronov et al., 2002). Conversely, IL-1β is an essential component of the 
response to infection and thus tight regulation of its levels are required for overall health 
(Dinarello, 2009). Thus, any agent that causes dysregulation of IL-1β levels has the potential 
to cause either unwanted inflammation or an inability to mount a competent immune 
response to infection.
DBT is considered to be an immunotoxin (Seinen et al., 1977; Whalen et al., 1999). It 
decreases the ability of human NK cells to destroy tumor cells with accompanying decreases 
in cytotoxic and cell surface protein expression (Dudimah et al., 2007; Catlin et al., 2005; 
Whalen et al., 2002). In addition, DBT alters the secretion of tumor necrosis factor alpha 
(TNFα) and interferon gamma (IFNγ) from human lymphocytes (Hurt et al., 2013; 
Lawrence et al., 2015). We recently demonstrated that another organotin, TBT modifies the 
secretion of IL-1β from human immune cells (Brown and Whalen, 2015). Based on DBT’s 
effect on TNFα and IFNγ secretion (Hurt et al., 2013; Lawrence et al., 2015) and TBT’s 
effect on IL-1β (Brown and Whalen, 2015), we hypothesize that exposure to DBT will alter 
the ability of immune cells to secrete IL-1β.
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In this study, an assortment of immune cell preparations was examined for the effects of 
DBT exposures on the secretion of IL-1β. The preparations studied included: human NK 
cells, human monocyte-depleted (MD) peripheral blood mononuclear cells (PBMCs) (MD-
PBMCs), PBMCs, PBMCs combined with granulocytes (PBMCs+granulocytes), and 
granulocytes. The use of increasingly reconstituted immune cell preparations allows us to 
investigate the influence that various immune cell types may have on the ability of DBT to 
induce alteration in secretion of IL-1β and may more accurately reflect physiological 
circumstances. An additional goal of this study is to investigate the signaling pathways that 
may be involved in any DBT-induced increases in IL-1β secretion.
Materials and Methods
Preparation of PBMCs, MD- PBMCs, and Granulocytes
PBMCs were isolated from Leukocyte filters (PALL- RCPL or RC2D) obtained from the 
Red Cross Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. 
Leukocytes were retrieved from the filters by back-flushing them with an elution medium 
(sterile phosphate buffered saline (PBS) pH 7.4 containing 5 mM disodium EDTA and 2.5% 
[w/v] sucrose) and collecting the eluent. The eluent was layered onto Ficoll-Hypaque (1.077 
g/mL) and centrifuged at 1200 g for 30–50 min. Granulocytes and red cells pelleted at the 
bottom of the tube while the PBMCs floated on the Ficoll-Hypaque. Mononuclear cells were 
collected and washed with PBS (500 g, 10 min). Following washing, the cells were layered 
on bovine calf serum for platelet removal. The cells were then suspended in RPMI-1640 
complete medium which consisted of RPMI-1640 supplemented with 10% heat-inactivated 
bovine calf serum (BCS), 2 mM L-glutamine and 50 U penicillin G with 50 μg 
streptomycin/mL. This preparation constituted PBMCs. Monocyte-depleted PBMCs (10–
20% CD16+, 10–20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% CD14+) were prepared 
by incubating the cells in glass Petri dishes (150 × 15 mm) at 37 °C and air/CO2, 19:1 for 
1.5 h. This cell preparation is referred to as MD-PBMCs. Granulocytes were isolated with 
the removal of mononuclear and red blood cells as described in Kuijpers et al., 2013. 
Granulocytes were collected and washed with PBS (2500 rpm, 15min). Red blood cells were 
lysed with NH4CL isotonic solution (155mM NH4Cl, 10mM KHCO3, 0.1 mM EDTA) for 
10 min. Cells were then washed with PBS and centrifuged at 800g for 10 min. The cells 
were then suspended in RPMI-1640 complete medium supplemented with 10% heat-
inactivated BCS, 2 mM L-glutamine and 50 U penicillin G with 50 μg streptomycin/mL.
Preparation of NK cells
NK cells were prepared from buffy coats (from healthy adult donors) purchased from Key 
Biologics, LLC (Memphis, TN). NK cells were prepared using a rosetting procedure. 
RosetteSep human NK cell enrichment antibody cocktail (0.6–0.8 mL) (StemCell 
Technologies, Vancouver, British Columbia, Canada) was added to 45 mL of buffy coat. The 
mixture was incubated for 20 min at room temperature (~ 25° C). Approximately 8 mL of 
the mixture was layered onto 4 mL of Ficoll-Hypaque (1.077 g/mL) (MP Biomedicals, 
Irvine, CA) and centrifuged at 1200 g for 30–50 min. NK cells were collected and washed 
twice with PBS and stored in complete media (RPMI-1640 supplemented with 10% heat-
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inactivated BCS, 2 mM L-glutamine and 50 U penicillin G with 50 μg streptomycin/ml) at 1 
million cells/mL at 37 °C and air/CO2, 19:1.
Chemical Preparation
DBT was purchased from Sigma-Aldrich (96%) (St. Louis, MO). A DBT stock solution was 
prepared by dissolving DBT in dimethylsulfoxide (DMSO). Desired concentrations of DBT 
were prepared by dilution of the stock into cell culture media. The final concentration of 
DMSO for DBT exposures did not exceed 0.01%. Appropriate DMSO controls were run.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fisher Scientific (Pittsburgh, PA). The stock 
solution for each inhibitor was a 50 mM solution in dimethylsulfoxide (DMSO). Capase-1 
inhibitor II, p38 inhibitor (SB202190), MEK 1/2 inhibitor (U0126), and NFκB inhibitor 
(BAY11-7085) were prepared by dilution of the stock solution into cell culture media.
Cell Treatments
NK cells, MD-PBMCs, PBMCs, granulocytes (at a concentration of 1.5 million cells/mL), 
or PBMCs+granulocytes (at a concentration of 0.75 million cells/mL each) were treated with 
DBT at concentrations of 0.05–5 μM for 24 h, 48 h, or 6 days. Following the incubations, 
the cells were pelleted and supernatants were collected and stored at −70° C until assaying 
for IL-1β. For pathway inhibitor experiments, MD-PBMCs (at a concentration of 1.5 million 
cells/mL) were treated with pathway inhibitors 1 h before adding DBT at concentrations of 
0.05 and 0.1 μM for 24 h. Following the incubations, the cells were pelleted and 
supernatants were collected and stored at −70° C until assaying for IL-1β.
Cell Viability
Cell viability was assessed at the beginning and end of each exposure period. Viability was 
determined using the trypan blue exclusion method. Briefly, cells were mixed with trypan 
blue and counted using a hemocytometer. The total number of cells and the total number of 
live cells were determined for both control and treated cells to determine the percent viable 
cells.
IL-1β Secretion Assay
IL-1β levels were measured using the BD OptEIA™ Human IL-1β enzyme-linked 
immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). Briefly, a 96-well 
micro well plate, designed for ELISA (Fisher, Pittsburgh, PA), was coated with a capture 
antibody for IL-1β diluted in coating buffer. The plate was incubated with the capture 
antibody overnight at 4 °C. After incubation, the capture antibody was removed by washing 
the plate three times with wash buffer (PBS and 0.05% Tween-20). Assay diluent (PBS and 
bovine calf serum) was added to each well (blocking non-specific binding) and incubated at 
room temperature for 1h. The assay diluent was removed by washing the plate three times, 
and the cell supernatants and IL-1β standards were added to the coated plated and incubated 
for 2 h at room temperature. Following this incubation, the plate was thoroughly washed five 
times and then incubated for 1h with a detection antibody to IL-1β which was conjugated 
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with horseradish peroxidase. The excess detection antibody was removed by washing seven 
times and a substrate solution was added for 30 min at room temperature to produce a 
colored product. The incubation with the substrate was ended by addition of acid and the 
absorbance was measured at 450 nm on a Thermo Labsystems Multiskan MCC/340 plate 
reader (Fisher Scientific).
Statistical Analysis
Statistical analysis of the data was performed by using ANOVA and Student’s t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s t 
test, a p value of less than 0.05 was considered significant.
Results
Viability of NK cells, MD-PBMCs PBMCs, PBMCs+ Granulocytes, and Granulocytes 
exposed to DBT
Table 1 shows the effects of DBT exposures (0.05–5 μM) on the viability of NK cells, MD-
PBMCs, PBMCs, PBMCs+granulocytes, and granulocytes. Exposure of NK cells to 0.05–1 
μM DBT for 24 h had no effect on their viability as compared to the control. The higher 
concentrations of DBT (2.5 and 5 μM) caused some decrease (about 10%) in NK cell 
viability. Exposure at 48 h showed significant reductions in viability (around 35%) at 2.5 
and 5 μM. NK cells exposed to 0.05–1 μM DBT for 6 days showed no change in viability as 
compared to the control. MD-PBMCs and PBMCs both showed a significant decrease in 
viability with exposure to 2.5 and 5 μM DBT for 24 h (15% for MD-PBMCs and 25% for 
PBMCs). The viability of both MD-PBMCs and PBMCs at 48 h was also significantly 
decreased by exposure to 2.5 (38%) and 5 μM (35%) DBT. After 6 days of exposure, 
concentrations of 0.5, 1, 2.5 and 5 μM DBT caused decreases in viability of only the MD-
PBMCs. Exposure of PBMCs+granulocytes to 0.05–2.5 μM DBT for 24 h had no effect on 
viability compared to the control; whereas, the viability of granulocytes alone was not 
affected by any of the DBT exposures after 24 h. Exposure to 5 μM DBT for 48 h 
significantly diminished the viability of PBMCs+granulocytes as did 6 day exposures to 
0.5–5 μM DBT. After 6 days the viability of granulocytes was significantly decreased under 
all conditions (as would be expected), but the treated cells were no less viable than the 
control cells.
Viability of monocyte-depleted PBMCs with pathway inhibitors exposed to DBT
MD-PBMCs were treated with various signaling pathway inhibitors 1 hour prior to adding 
the appropriate concentrations of DBT (0.05 and 0.1 μM). The viability of all treatments was 
greater than 90%. (data not shown).
Effects of DBT Exposure on Secretion of IL-1β by NK cells
Table 2 shows the effects of exposing NK cells to DBT (0, 0.05, 0.1, 0.25, 0.05, 1, 2.5 and 5 
μM) on IL-1β secretion. Cells from 3 different donors were exposed to DBT for 24 h, 48 h, 
and 6 days (KB=Key Biologic buffy coat). All donors showed significant decreases in IL-1β 
secretion when exposed to 0.5, 1, 2.5, and 5 μM DBT at all lengths of exposure. 
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Additionally, 2 of the 3 donors showed increased IL-1 β secretion with exposures to 0.05 μM 
DBT after 24 and/or 48 h exposures.
Effects of DBT Exposure on Secretion of IL-1β by MD-PBMCs
The effects of exposures to DBT on secretion of IL-1β from MD-PBMCs from 5 donors 
(F=filter obtained from the Red Cross) are shown in Table 3. Exposure conditions were the 
same as for NK cells. This preparation mainly consists of NK cells and T cells. When MD-
PBMCs were exposed to DBT for 24 h there were statistically significant increases in IL-1β 
secretion induced by DBT (all donors) at the 0.05 μM concentration with variation in the 
fold increase among different donors. F142 showed a 1.5 fold increase while F166 showed a 
3.0 fold increase. Some donors showed increases in IL-1β at additional concentrations of 
DBT. Significant decreases in IL-1β secretion were seen at 1, 2.5, and 5 μM DBT (cells 
from all donors) after a 24 h exposure. The results seen after 48 h and 6 day exposures to 
DBT were similar to those seen after 24 h.
Effects of DBT Exposure on Secretion of IL-1β by PBMCs
Table 4 summarizes the effects of exposing PBMCs from 4 individual donors to DBT on 
IL-1β secretion (F=filter obtained from the Red Cross). A 24 h exposure to 2.5 and 5 μM 
DBT caused a significant decrease (P<0.05) in IL-1β secretion in cells from all donors and 
at 1 μM DBT for 3 of the 4 donors. Significant increases in IL-1β secretion were seen (all 
donors) at 0.1 μM and in 3 of the 4 donors at 0.05 μM. Again, the magnitude of DBT-
induced increases in IL-1β secretion was donor dependent. For instance, cells from donor 
F159 treated with 0.05, 0.1, and 0.25 μM DBT showed significant increases of 1.7, 3.8, and 
3.4 fold, respectively. 48 h exposures of PBMCs to 0.5, 1, 2.5 and 5 μM DBT caused 
significant decreases in IL-1β for donor F154. Significant increases were also seen at some 
of these same concentrations for donors F159 and F173. After 6 days of exposure, 
significant decreases in IL-1β secretion were seen in cells from all donors when exposed to 
2.5 and 5 μM DBT. Significant increases in IL-1β secretion were seen inall donors at 0.25 
μM DBT.
Effects of DBT Exposure on Secretion of IL-1β by PBMCs+Granulocytes
Effects of exposing PBMCs+granulocytes (prepared from the same 4 donors as PBMCs) to 
DBT on IL-1β secretion are shown in Table 5 (F=filter obtained from the Red Cross). Like 
the previous cell types discussed, the concentrations that caused increases and decreases in 
IL-1β secretion varied from one donor to the next at all lengths of exposures. After 24 h 
exposures to 2.5 and 5 μM DBT, there were significant decreases in IL-1β secretion in cell 
from 3 of the 4 donors. There were also significant increases in IL-1β secretion over the 
range of 0.05–2.5 μM DBT (all donors). The specific concentration(s) at which the 
increase(s) were seen varied among donors. For example, cells from donor F159 treated with 
0.25, 0.5, and 1 μM DBT showed fold increases at 1.9, 1.8, and 1.8, respectively at 24 h and 
35, 56, and 77 fold, respectively at 48 h. After 6 days, control cells no longer demonstrated 
any meaningful secretion of IL-1β (detection limit of the assay was 3 pg/mL). However, the 
cells from donors F154 and F159 did show secretion when exposed to certain concentrations 
of DBT.
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Effects of DBT Exposure on Secretion of IL-1β by Granulocytes
The effects of exposures to DBT on secretion of IL-1β were examined in granulocytes 
prepared from the same 4 donors as were PBMCs. Secretion of IL-1β was not above the 
limit of detection (3 pg/mL) under any of the conditions tested after 24 h. However after 48 
h, cells from 3 of the 4 donors showed DBT-induced increases in IL-β secretion. The DBT-
stimulated increases in secretion occurred over the concentration range of 0.25–5 μM. The 
data from a representative donor (F173) are shown in Figure 1. Although IL-1β secretion 
was lower for granulocytes than all other cell types tested, there were still significant 
increases in IL-1β secretion induced by DBT in two of the three donors.
Effects of DBT Exposure on Secretion of IL-1β by MD-PBMCs treated with Selective 
Signaling Pathway Inhibitors
IL-1β Cleavage Inhibitor (Caspase-1 Inhibitor II)—The effects of exposures to 0.05 
and 0.1 μM DBT on secretion of IL-1β from MD-PBMCs where Caspase-1 had been 
inhibited with Caspase-1 inhibitor II (50 μM) are shown in Table 6. Since this enzyme is 
required for IL-1β processing, Caspase-1 inhibitor II significantly decreased (p<0.05) 
baseline IL-1β production in cells from each donor. Figure 2A shows the fold increases from 
a representative experiment (F245). There were 1.8 fold increases when MD-PBMCs were 
exposed to 0.05 and 0.1 μM DBT in the absence of the Caspase-1 inhibitor. When the 
inhibitor was present those same DBT exposures caused 1.4 fold and no increase in IL-1β 
secretion. Thus, DBT showed diminished ability to increase IL-1β secretion in 4 of the 5 
donors. However, in cells from 1 of the donors DBT-induced increases in Il-1β secretion 
were unaffected by the Caspase I inhibitor. This indicates that Caspase-1 is likely needed for 
DBT to cause increased IL-1β secretion. However, this requirement varies among donors.
Nuclear Factor kappa B (NFκB) Inhibitor (BAY 11-7085)—Table 6 also shows the 
effects of exposures to 0.05 and 0.1 μM DBT on secretion of IL-1β from MD-PBMCs where 
NFκB function had been inhibited with BAY 11-7085. BAY 11-7085 had varying effects on 
baseline IL-1β secretion. Cells exposed to DBT when the inhibitor was present showed no 
substantial change in DBT-stimulated secretion of IL-1β. For instance, when cells from 
donor F244 were exposed to 0.05 and 0.1 μM DBT in the absence of NFκB inhibitor there 
were 1.2, and 1.3 fold increases in IL-1β secretion and when the inhibitor was present those 
same DBT exposures caused 1.3 and 1.3 fold increases in IL-1β secretion (Figure 2B). Thus, 
unlike the Caspase-1, these results suggest that NFκB is not utilized by DBT to increase the 
secretion of IL-1β from the cells.
Mitogen activated protein kinase kinase (MAP2K), MEK, Inhibitor (U0126)—The 
effects of inhibiting the p44/42 mitogen activated protein kinase (MAPK) pathway with 
U0126 (50 μM) on DBT-induced increases in IL-1β secretion are shown in Table 6. When 
this pathway was inhibited the ability of DBT to increase IL-1β secretion was markedly 
diminished or blocked completely. For example, cells from donor F240 showed 1.6 fold 
increases in IL-1β when exposed to 0.05 and 0.1 μM DBT in the absence of MEK inhibitor 
and no DBT-induced increases in IL-1β secretion when the inhibitor was present (Figure 
2C). This same effect was seen in the cells from each of the 4 donors tested. This indicates 
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that the p44/42 MAPK pathway is being utilized by DBT to lead to the increase in IL-1β 
secretion.
p38 Inhibitor (SB202190)—The effects of p38 MAPK pathway inhibition on DBT-
induced increases in IL-1β secretion from MD-PBMCs are shown in Table 6. In 3 of the 4 
donors the p38 inhibitor significantly decreased baseline secretion, and in 1 donor it greatly 
increased secretion. In Figure 2D we see there were 7.2 and 2.5 fold increases when MD-
PBMCs (donor F247) were exposed to 0.05 and 0.1 μM DBT in the absence of p38 inhibitor. 
When the inhibitor was present those same DBT exposures caused no increases in IL-1β 
secretion. This effect was consistent in cells from all donors (Table 6). This indicates that the 
p38 pathway is being utilized by DBT to stimulate IL-1β secretion.
Discussion
DBT is mainly used as a stabilizer in PVC plastics (Forsyth et al., 1992, 1997; Sadiki et al., 
1996) and levels as high as 0.3 μM have been found in human blood samples (Kannan et al., 
1999; Whalen et al., 1999). DBT decreases the ability of human NK cells to destroy tumor 
cells (Dudimah et al., 2007; Catlin et al., 2005; Whalen et al., 2002). It also alters the 
secretion of tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) from human 
lymphocytes (Hurt et al., 2013; Lawrence et al., 2015). IL-1β is an inflammatory cytokine 
that contributes to normal immune responsiveness (Dinarello, 2009). However, when its 
levels are inappropriately elevated it causes chronic inflammation which can increase tumor 
invasiveness (Voronov et al., 2003). Thus, tight regulation of IL-1β levels is required for 
maintaining health. We investigated whether DBT alters the secretion of IL-β from immune 
cells in an ex vivo human model. Increasingly reconstituted human immune cell preparations 
were used (NK cells, MD-PBMCs, PBMCs, PBMC+granulocytes, and granulocytes) to 
determine if the complexity of the cell preparation influences the effects of DBT. 
Furthermore, experiments to identify signaling pathways involved in DBT-induced increases 
of IL-1β levels were also performed.
DBT induced both increases and decreases in IL-1β secretion from immune cells. Higher 
concentrations of DBT (5 and 2.5 μM) tended to decrease IL-1 β secretion from all immune 
cell preparations and effects varied somewhat in a donor dependent manner. Lower 
concentrations stimulated IL-1β secretion in the cell preparations. Higher concentrations of 
DBT will be able to bind to a wider range of cellular targets than will lower concentrations, 
based on DBT’s affinity for specific cellular components. Thus, far fewer target molecules 
will be bound by lower concentrations of DBT and this may account for the opposite effects 
of higher concentrations of DBT versus lower concentrations on IL-1β secretion. For 
instance at 5 μM, DBT may be able to bind cellular components that result in blocking either 
IL-1β synthesis and/or secretion and these effects may overwhelm the effects of binding to 
any cellular components that increase IL-1β synthesis/secretion. However, at 0.05 μM the 
DBT may be binding predominantly to components that stimulate synthesis/secretion. The 
concentration at which DBT caused the maximum fold increase in IL-β secretion from each 
of the different cell types (after 24 h of exposure) varied among the donors. The average of 
the maximum fold increase was similar for all cell preparations: NK cells 3.5-fold (ranging 
from 1.0- to 8.0-fold); MD-PBMCs 2.0-fold (ranging from 1.5- to 3.0-fold); PBMCs 3.2 fold 
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(ranging from 2.1- to 3.8-fold); PBMCs+granulocytes 3.8-fold (range of 1.5- to 9.2-fold); 
and granulocytes 3.7-fold (ranging from 1.3- to 12-fold). Granulocytes alone showed very 
low or no baseline secretion of IL-1β (depending on the donor). Granulocytes have been 
shown by others to be capable of secreting IL-1β (Guma et al., 2009).
The viability of the NK cells, MD-PBMCs, PBMCs, and PBMCs+granulocytes was 
decreased significantly after all lengths of exposure at the higher concentrations of DBT. For 
instance after a 24 h exposure to 5 μM DBT there were average decreases in the viability of 
NK, MD-PBMC, PBMC, and PBMC+granulocytes of 13%, 15%, 31%, 16%, respectively. 
However, the decreases in viability seen at those concentrations were not sufficient to 
account for the very large decreases in IL-1β secretion seen in the vast majority of donors. 
Additionally, it has been shown that cell death can act as a stimulator of IL-1β secretion 
(Lopez-Castejon and Brough, 2011) and would not necessarily be expected to decrease 
secretion. Thus, it appears that the decreases in IL-1β secretion seen after 24 h are not due to 
cell death but to some inhibitory effect of DBT on the ability of the immune cells to secrete 
IL-1β.
Many signaling pathways are involved in the production and secretion of IL-1β from human 
immune cells. These pathways include Caspase 1, NFκB, and MAPKs (p44/42 and p38). 
Our results indicate that three of these pathways appear to be involved in DBT-induced 
increases in IL-1β secretion. Inhibition of Caspase-1, the enzyme that is needed for secretion 
of IL-1β from human immune cells, tended to diminish DBT-induced secretion. Thus, 
Caspase-1 appears to be one of the cellular components/pathways that DBT interacts with in 
causing increased IL-1β secretion. NFκB is needed as a transcription factor for several 
cytokine genes including IL-1β (Cogswell et al., 1994; Perez et al., 1999; Scheibel et al., 
2010). However, the data indicated that DBT-induced IL-1β secretion did not require the 
NFκB pathway. The p44/42 MAPK (ERK 1 and ERK 2) is an important regulator of cell 
growth (Cowley et al., 1994; Hunter, 1995; Marshall, 1995). Once activated, p44/42 leads to 
activation of the transcription regulator AP-1 (comprised of fos and jun), and activation of 
AP-1 leads to increased transcription of IL-1β (Glauser and Schlegel, 2007). When the 
p44/42 pathway was inhibited by an MEK inhibitor, DBT-induced increases in IL-1β 
secretion were diminished or blocked. Thus, DBT may be activating the p44/42 pathway 
which then leads to an increase in IL-1β secretion. The MAPK, p38, has also been shown to 
regulate cytokine production (Davis, 1995; Young et al., 1997). This includes activation of 
IL-1β gene transcription by way of C/EBPβ/NFIL-6 transcription activator (Baldassare et 
al., 1999). Inhibition of the p38 pathway diminished the ability of at least one concentration 
of DBT to stimulate IL-1β secretion in all donors tested. Thus it appears that the p38 
pathway is likely being utilized by DBT to stimulate IL-1β secretion. Figure 3 summarizes 
the pathways that may possibly be involved in the regulation of secretion and synthesis 
relating to IL-1β.
In a previous study, we showed that TBT increased IL1β secretion from immune cells at 
certain concentrations in a donor dependent manner (Brown and Whalen; 2015). We were 
able to carry out the study of both TBT and DBT in NK cells prepared from a single donor 
(KB169). IL-1β increased 7.7-, and 6.3-fold at 50 and 100 nM TBT (Brown and Whalen, 
2015). These same cells showed increased IL-1β secretion of 7.9 and, 6.0 fold at 0.05 μM 
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(50 nM) and 0.1 μM (100 nM) DBT. These results suggest that TBT and DBT at the same 
concentrations caused roughly similar stimulation of IL-1β secretion in this one donor. 
However, when we looked at both chemicals in MD-PBMCs for 3 common donors (F142, 
F145, and F152), 24 h exposures to TBT, caused significant increases of 2.1 and 1.8 fold at 
the 50 and 100 nM concentrations in cells from donor F142 (Brown and Whalen, 2015) 
while DBT at these same concentrations caused increases of 1.5 and 1.6 fold. In cells from 
donor F145, 50 and 100 nM TBT caused increases of 1.8 and 1.5 fold while DBT caused an 
increase of 1.5 fold at 50 nM and no increase at 100 nM. The cells from the third common 
donor showed increases of 11 and 33 fold with 50 and 100 nM TBT and increases of 2.1 and 
1.4 fold with these same concentrations of DBT. Taken together, these comparisons indicate 
that DBT may be generally less effective at inducing an increase in IL-1β secretion than is 
TBT. This may be due to the fact that DBT is less hydrophobic than TBT due to the loss of 
the third butyl group (Laughlin et al., 1986; Harper, 2005) and is thus less able to enter the 
cell to bind to intracellular targets (such as MAPKs) that appear to be involved in the 
compound-induced increases in IL-1β secretion. It may also mean that DBT simply has a 
lower affinity for those intracellular components and thus is somewhat less effective at 
inducing the effect.
Previously we found that, MAPKs (p44/42 and p38) were needed for TBT-induced secretion 
of IL-1β in MD-PBMCs (Brown and Whalen; 2015). The present study indicates that 
Caspase 1 and MAPKs (p44/42 and p38) are being utilized in DBT-induced secretion of 
IL-1β in MD-PBMCs. This suggests that DBT is able to interact with the Caspase 1 pathway 
while TBT does not. The ability to compare the effects of TBT and DBT gives a clearer 
understanding of the similarities and differences of their effects on immune cells. Beyond 
the common effects that we have noted on cytokine secretion, they have also both been 
shown to induce apoptosis of thymocytes in vitro (Gennari et al., 1997). Furthermore they 
have been shown to cause degeneration of the thymus (maturation site of T-cells) in rats 
(Snoeij et al., 1988).
In summary, the current study demonstrates that DBT alters IL-1β secretion from 
increasingly reconstituted preparations of human immune cells. Higher concentrations of 
DBT (5 and 2.5 μM) decreased the secretion of IL-1β, while lower concentrations (0.1 and 
0.05 μM) increased the secretion of IL-1β. These results suggest that DBT-induced 
alterations of IL-1β secretion from immune cells may potentially affect immune function 
and cancer invasiveness. The levels of DBT found in human blood samples (0.3 μM and 
below) fall in the range of DBT concentrations that elevated IL-1β levels in this study and 
thus DBT may be more of problem in terms of causing chronic inflammation rather than loss 
of immune competence in exposed individuals. This study also indicates that components of 
Caspase 1 and MAPKs (p44/42 and p38) pathways are targets of DBT. The MAPK 
pathways are known to lead to increased transcription of the IL-1β gene (Baldassare et al., 
1999; Cogswell et al., 1995; Glauser and Schlegel, 2007; Guma et al., 2009; Perez et al., 
1999; Scheibel et al., 2010), suggesting that DBT is increasing IL-1β transcription as one of 
its effects on immune cells.
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Granulocytes exposed to 0–5 μM DBT at 48 h exposure (donor F173), asterisk indicates a 
significant difference from control
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Effects of 24 h exposure to 0.05 and 0.1 μM DBT on IL-1β secretion from monocyte-
depleted PBMCs treated with selective pathway component inhibitors in individual donors. 
A) IL-1β Cleavage Inhibitor (Caspase-1 Inhibitor II) (donor F245). B) NFκB Inhibitor (BAY 
11-7085) (donor F244). C) MEK 1/2 (p44/42) Inhibitor (U0126) (donor F240). D) p38 
Inhibitor (SB202190) (donor F247).
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Signaling pathways regulating IL-1β secretion.
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Table 2
Effects of 24 h, 48 h, 6 day exposures to DBT on IL-1β secretion from highly purified human NKs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM KB130 KB155 KB169
0 249±20 3110±238 196±13
0.05 386±41* 2965±1004 1551±25*
0.1 116±27* 2771±70 1173±69*
0.25 17±20* 779±25* 796±137*
0.5 ND* 28±23 114±21*
1 ND* ND* ND*
2.5 ND* ND* ND*
5 ND* ND* ND*
48 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM KB130 KB155 KB169
0 452±17 4916±116 186±13
0.05 1372±481 5235±531 341±10*
0.1 298±65* 4588±130* 367±53*
0.25 139±46* 1598±450* 262±14*
0.5 ND* 130±39* ND*
1 ND* ND* ND*
2.5 ND* ND* ND*
5 ND* ND* ND*
6day Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM KB130 KB155 KB169
0 600±97 1472±182 615±93
0.05 782±35 1625±164 453±91
0.1 550±21 1572±245 602±257
0.25 142±27* 960±152* 511±227
0.5 46±53* 138±43* 157±61*
1 ND* ND* ND*
2.5 ND* ND* ND*
5 ND* ND* ND*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05.
ND = not detectable. The limit of detection on the assay is 3 pg/mL
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Table 4
Effects of 24 h, 48 h, 6 day exposures to DBT on IL-1β secretion from PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM F148 F154 F159 F173
0 65733±3402 1611±98 1692±204 5331±216
0.05 120533±8211* 5056±273* 2812±150* 7072±935
0.1 107467±4636* 4568±168* 6376±233* 8100±822*
0.25 137333±3926* 1383±123 5803±150* 4443±405*
0.5 32400±1833* 765±84* 1667±112 20063±1077*
1 11600±11085* 380±13* 812±65* 9989±155*
2.5 12133±462* 111±67* ND* 3813±58*
5 11867±924* ND* ND* 2517±73*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DBT] μM F148 F154 F159 F173
0 10041±316 1944±56 346±36 436±15
0.05 15851±836* 4249±294* 1034±299 614±63*
0.1 17620±257* 4193±556* 1211±71* 500±41
0.25 18728±597* 1687±42* 1243±192* 425±20
0.5 5493±409* 1036±128* 1099±93* 745±36*
1 2224±329* 1325±72* 1246±9* 2064±194*
2.5 ND* 378±61 532±101 591±32*
5 483±358* 193±0* 565±15* 478±32
6day Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DBT] μM F148 F154 F159 F173
0 21±0 1589±24 91±2 376±18
0.05 ND* 3507±155* 210±62 465±151
0.1 25±0* 3300±114* 236±10* 398±28
0.25 25±1* 3816±464* 507±21* 453±16*
0.5 6±0* 2056±114* 229±7* 932±8*
1 ND* 2531±464 256±12* 690±15*
2.5 ND* 586±179* 52±1* 181±8*
5 ND* 118±146* 51±9* 145±2*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05.
ND = not detectable.
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Table 5
Effects of 24 h, 48 h, 6 day exposures to DBT on IL-1β secretion from PBMCs plus Granulocytes
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM F148 F154 F159 F173
0 2972±267 900±38 329±26 143±7
0.05 4217±397* 1364±181* 438±18* 150±26
0.1 3060±191 1059±141 375±28 168±34
0.25 3344±212 835±38 648±18* 146±12
0.5 7275±2061 538±33* 620±40* 165±13
1 2011±148* 386±157* 617±74* 632±19*
2.5 736±552* ND* 87±12* 287±22*
5 197±78* ND* ND* 140±10
48 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM F148 F154 F159 F173
0 492±25 320±10 4±3 26±2
0.05 646±25* 358±88 109±93 57±35
0.1 864±11* 346±40 48±8* 17±2*
0.25 1017±76* 372±47 141±16* 42±6*
0.5 1191±200* 372±24* 226±16* 32±1*
1 491±26 322±11 311±39* 160±2*
2.5 ND* 321±35 505±54* 124±3*
5 ND* 321±20 192±15* 63±1*
6day Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DBT] μM F148 F154 F159 F173
0 ND 3±0 ND ND
0.05 ND 65±34 3±2 ND
0.1 ND 31±16 3±2 ND
0.25 ND 8±1* ND ND
0.5 3±1 11±0* 5±1* ND
1 ND 10±0* 5±1* ND
2.5 ND 3±0 7±1* ND
5 ND ND ND ND
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05.
ND = not detectable.
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